N-fluorenylmethoxycarbonyl-L-2-amino-5-phenylpentanoic acid or pharmaceutical composition and application thereof
By preparing a pharmaceutical composition containing N-fluorenylmethoxycarbonyl-L-2-amino-5-phenylvaleric acid, the problem of structural deficiency in existing lipid-regulating drugs has been solved, achieving the reduction of serum cholesterol, triglycerides, and low-density lipoprotein cholesterol, and the increase of high-density lipoprotein cholesterol, providing an effective treatment and prevention approach for hyperlipidemia.
Patent Information
- Application Number
- CN202511217295.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-08-28
- Publication Date
- 2025-10-24
AI Technical Summary
Existing clinical lipid-regulating drugs lack structures that can lower total cholesterol, triglycerides, and low-density lipoprotein cholesterol, and raise high-density lipoprotein cholesterol, and there are no related applications of N-fluorenemethoxycarbonyl-L-2-amino-5-phenylpentanoic acid compounds.
A pharmaceutical composition is prepared by using N-fluorenylmethoxycarbonyl-L-2-amino-5-phenylvaleric acid as the active ingredient and combining it with pharmaceutical excipients. This composition is used to prepare drugs that lower serum total cholesterol, triglycerides, and low-density lipoprotein cholesterol while raising high-density lipoprotein cholesterol. It is suitable for the prevention and treatment of hyperlipidemia.
It significantly modulates serum lipid levels in a mouse model induced by a high-fat, high-cholesterol diet, reducing total cholesterol and triglycerides, decreasing low-density lipoprotein cholesterol, and increasing high-density lipoprotein cholesterol, providing an effective means of prevention and treatment for hyperlipidemia.
Smart Images

Figure CN120827549A_ABST
Abstract
Description
TECHNICAL FIELD
[0001] The present application relates to the technical field of biological medicine, more particularly, to N-Fluorenylmethoxycarbonyl-L-2-amino-5-phenylvaleric acid or a pharmaceutical composition thereof and application. BACKGROUND
[0002] Blood lipids refer to lipids contained in plasma or serum, including cholesterol (CH), triglyceride (TG), phospholipid (PL) and free fatty acid (FFA) and the like. Cholesterol is divided into cholesteryl ester and free cholesterol, and the sum of the two is total cholesterol (TC). Blood lipids are combined with apolipoprotein to form lipoprotein, which is dissolved in plasma for transport and metabolism. Lipoprotein can be divided into chylomicron, very low density lipoprotein, low density lipoprotein, medium density lipoprotein and high density lipoprotein by electrophoresis and ultracentrifugation according to its composition, density and characteristics.
[0003] Lipid metabolism is a complex process, including synthesis and transport of TG, synthesis and beta-oxidative decomposition of fatty acids, and metabolism of cholesterol. The network of body lipid metabolism is complex and is regulated by multiple tissues and organs such as liver, intestine and fat. When the intake and consumption, synthesis and decomposition metabolism of energy in the human body are in a long-term imbalance, it will lead to lipid metabolism disorder.
[0004] Hyperlipidemia is a common lipid metabolism disorder disease, characterized by elevated serum total cholesterol (TC), triglyceride (TG) and low density lipoprotein cholesterol (LDL-C) levels or reduced high density lipoprotein cholesterol (HDL-C) levels.
[0005] Hyperlipidemia can be divided into primary and secondary. The primary one is related to congenital and heredity, caused by single gene defect or multiple gene defects, abnormal receptors, enzymes or apolipoproteins involved in lipoprotein transport and metabolism, or caused by environmental factors (diet, nutrition, drugs) and unknown mechanisms. The secondary one is secondary to metabolic disorders (diabetes, hypertension, myxedema, hypothyroidism, obesity, liver and kidney diseases, adrenal cortex hyperfunction), or related to other factors (age, gender, season, drinking, smoking, diet, physical activity, mental stress, emotional activity). Hyperlipidemia is one of the main risk factors for atherosclerosis, coronary heart disease, myocardial infarction, stroke and other cardiovascular and cerebrovascular diseases.
[0006] The currently clinically used lipid regulating drugs mainly include: fibric acid, such as gemfibrozil, bezafibrate, fenofibrate, ciprofibrate, etc., which can activate peroxisome proliferator-activated receptor alpha (PPARa) in the liver, increase the activity of lipoprotein lipase (LPL enzyme), and reduce triglyceride and cholesterol. Statins, i.e. 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, such as lovastatin, pitavastatin, pravastatin, atorvastatin, rosuvastatin, etc., which can inhibit the key enzyme HMG-CoA reductase in the body to mainly reduce cholesterol, have strong lipid-lowering effect and fast onset. Nicotinic acid, a B group vitamin derivative, mainly includes nicotinic acid, nicotinic acid vitamin E ester, nicotinic acid myo-inositol ester, acipimox (Lezhi Ping), etc., which can inhibit the activity of glycerol diesterase in adipose tissue to inhibit the mobilization of adipose tissue, reduce the mobilization of free fatty acids in the triglyceride pool in adipose tissue, and reduce the content of free fatty acids in plasma, thereby reducing the synthesis of TG in the liver and the secretion of very low density lipoprotein (VLDL). Polyenes, which are polyunsaturated fatty acids, have a lipid-lowering mechanism of combining with TC to form esters, promoting the degradation of TC into bile acids and excretion with bile, thereby reducing the concentration of TC and TG in blood, and having little effect on the levels of HDL-C and LDL-C, and are mainly used for treating hypertriglyceridemia. Polyene lipid-lowering drugs are divided into two categories according to components: the first category is N-6 fatty acid, mainly linoleic acid, which has weak lipid-lowering effect and is suitable for mild hyperlipidemia, and the compound preparations include Yishuneng, Yueshicaomao pill, and Duo'enyikang pill, etc.; the second category is fish oil preparation, mainly linolenic acid, which is called N-3 fatty acid, and has stronger lipid-lowering effect than the former, mainly including eicosapentaenoic acid and docosahexaenoic acid. Cholesterol absorption inhibitor, represented by Ezetimibe, which can combine with bile acids, block the reabsorption of bile acids, promote the conversion of cholesterol into bile acids, and thereby reduce the cholesterol in the body.
[0007] The currently clinically used lipid regulating drugs have no similar structure to the N-fluorenylmethoxycarbonyl-L-2-amino-5-phenylvaleric acid described in the present application, and there is no related report on using the N-fluorenylmethoxycarbonyl-L-2-amino-5-phenylvaleric acid described in the present application in drugs. SUMMARY
[0008] The present application discloses N-fluorenylmethyloxycarbonyl-L-2-amino-5-phenyl pentanoic acid with the structure shown in formula (I) which has the effect of reducing total cholesterol, triglyceride, low density lipoprotein cholesterol in serum and increasing high density lipoprotein cholesterol in serum, and the application of the N-fluorenylmethyloxycarbonyl-L-2-amino-5-phenyl pentanoic acid in the preparation of a medicine for reducing total cholesterol in serum, a medicine for reducing triglyceride in serum, a medicine for reducing low density lipoprotein cholesterol in serum or a medicine for increasing high density lipoprotein cholesterol in serum, and the application of the N-fluorenylmethyloxycarbonyl-L-2-amino-5-phenyl pentanoic acid in the preparation of a medicine for preventing or treating hyperlipidemia.
[0009] The above object of the present application is achieved by the following technical solutions. A pharmaceutical composition comprises N-fluorenylmethyloxycarbonyl-L-2-amino-5-phenyl pentanoic acid and pharmaceutically acceptable excipients, and the structure of the N-fluorenylmethyloxycarbonyl-L-2-amino-5-phenyl pentanoic acid is shown in formula (I).
[0010] Formula (I).
[0011] N-fluorenylmethyloxycarbonyl-L-2-amino-5-phenyl pentanoic acid (common name: Fmoc-2-amino-5-phenyl-pentanoic acid; English name: Fmoc-L-2-Amino-5-phenyl-pentanoic acid; abbreviation: F2A5PP).
[0012] In some specific embodiments, the pharmaceutically acceptable excipients comprise pharmaceutically acceptable salts or esters.
[0013] In some specific embodiments, the pharmaceutically acceptable salts are choline salt compounds.
[0014] In some specific embodiments, the pharmaceutically acceptable esters are isopropyl ester compounds.
[0015] In some specific embodiments, the pharmaceutically acceptable excipients comprise adhesives, fillers, disintegrants, lubricants, antioxidants, flavorings, fragrances, cosolvents, emulsifiers, solubilizers, osmotic pressure regulators, colorants.
[0016] The present application also protects the use of N-fluorenylmethyloxycarbonyl-L-2-amino-5-phenyl pentanoic acid or the above-mentioned pharmaceutical composition in the preparation of a medicine for reducing total cholesterol in serum, and the structure of the N-fluorenylmethyloxycarbonyl-L-2-amino-5-phenyl pentanoic acid is shown in formula (I).
[0017] Formula (I).
[0018] The present application also protects the use of N-Fluorenylmethoxycarbonyl-L-2-amino-5-phenylvaleric acid or the above-mentioned pharmaceutical composition in the preparation of a medicament for lowering serum triglyceride, wherein the structural formula of the N-Fluorenylmethoxycarbonyl-L-2-amino-5-phenylvaleric acid is shown as formula (I):
[0019] Formula (I).
[0020] The present application also protects the use of N-Fluorenylmethoxycarbonyl-L-2-amino-5-phenylvaleric acid or the above-mentioned pharmaceutical composition in the preparation of a medicament for lowering serum low density lipoprotein cholesterol, wherein the structural formula of the N-Fluorenylmethoxycarbonyl-L-2-amino-5-phenylvaleric acid is shown as formula (I):
[0021] Formula (I).
[0022] The present application also protects the use of N-Fluorenylmethoxycarbonyl-L-2-amino-5-phenylvaleric acid or the above-mentioned pharmaceutical composition in the preparation of a medicament for lowering serum low density lipoprotein cholesterol, wherein the structural formula of the N-Fluorenylmethoxycarbonyl-L-2-amino-5-phenylvaleric acid is shown as formula (I):
[0023] Formula (I).
[0024] The present application also protects the use of N-Fluorenylmethoxycarbonyl-L-2-amino-5-phenylvaleric acid or the above-mentioned pharmaceutical composition in the preparation of a medicament for lowering serum low density lipoprotein cholesterol, wherein the structural formula of the N-Fluorenylmethoxycarbonyl-L-2-amino-5-phenylvaleric acid is shown as formula (I):
[0025] Formula (I).
[0026] In some specific embodiments, the pharmaceutical excipient further comprises a pharmaceutical carrier.
[0027] In some specific embodiments, the corresponding pharmaceutical dosage form is prepared by mixing N-Fluorenylmethoxycarbonyl-L-2-amino-5-phenylvaleric acid as an active ingredient with a pharmaceutical carrier. The carrier includes a solid dispersion carrier, a nanoparticle carrier, a liposome, a microcapsule and a microsphere, etc.
[0028] In some specific embodiments, the pharmaceutical dosage form is an aqueous solution, a non-aqueous solution, a suspension, a tablet, a capsule, a granule or an infusion.
[0029] In some embodiments, the daily dosage of N-Fluorenylmethoxycarbonyl-L-2-amino-5-phenylvaleric acid is 10-500 mg, and the optimal daily dosage is 100-200 mg. The administration can be once or several times a day.
[0030] The mode of administration of the N-Fluorenylmethoxycarbonyl-L-2-amino-5-phenylvaleric acid or pharmaceutical composition of the present application is not particularly limited, and representative modes of administration include, but are not limited to, oral, parenteral (intravenous, intramuscular or subcutaneous) and topical administration.
[0031] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier) or with the following ingredients: (a) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and silicic acid; (b) binders, such as hydroxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia; (c) disintegrants, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (d) humectants, such as glycerol and
[0032] In addition to such inert diluents, the formulations can include adjuvants, such as wetting agents and suspending agents, sweetening, flavoring, and perfuming agents.
[0033] Formulations for parenteral injection can include physiologically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and nonaqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.
[0034] Dosage forms of the compounds of the present application for topical administration include ointments, powders, patches, sprays, and inhalers. The active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants that can be required.
[0035] Compared with the prior art, the present application has the following beneficial technical effects: The N-fluorenylmethoxycarbonyl-L-2-amino-5-phenylpentanoic acid or pharmaceutical composition of the present invention can significantly regulate the blood lipid level in the serum of a mouse model induced by a high-fat and high-cholesterol diet, has the effects of reducing total cholesterol, triglycerides, and low-density lipoprotein cholesterol in the serum and increasing high-density lipoprotein cholesterol in the serum, thereby regulating blood lipids. The N-fluorenylmethoxycarbonyl-L-2-amino-5-phenylpentanoic acid or pharmaceutical composition of the present invention can be used to prepare drugs for reducing total cholesterol in serum, preparing drugs for reducing triglycerides in serum, preparing drugs for reducing low-density lipoprotein cholesterol in serum, or preparing drugs for increasing high-density lipoprotein cholesterol in serum. The N-fluorenylmethoxycarbonyl-L-2-amino-5-phenylpentanoic acid or pharmaceutical composition can be used alone or in combination with other drugs to prepare drugs for preventing or treating hyperlipidemia. BRIEF DESCRIPTION OF THE DRAWINGS
[0036] Figure 1 This is a comparison chart of the changes in total cholesterol (TC) after administration of N-Fmoc-L-2-amino-5-phenylpentanoic acid.
[0037] Figure 2 This is a comparison chart of triglyceride (TG) changes after administration of N-Fmoc-L-2-amino-5-phenylpentanoic acid.
[0038] Figure 3 This is a comparison chart of the changes in low-density lipoprotein cholesterol (LDL-C) after administration of N-fluorenylmethoxycarbonyl-L-2-amino-5-phenylpentanoic acid.
[0039] Figure 4 This is a comparison chart of the changes in high-density lipoprotein cholesterol (HDL-C) after administration of N-fluorenylmethoxycarbonyl-L-2-amino-5-phenylpentanoic acid.
[0040] Figure 5 This is a comparison chart of the changes in oxidized low-density lipoprotein (Ox-LDL) after administration of N-Fmoc-L-2-amino-5-phenylpentanoic acid. DETAILED DESCRIPTION
[0041] The present invention will be further described below in conjunction with specific embodiments, but the examples do not limit the present invention in any form. Unless otherwise specified, the raw materials and reagents used in the examples of the present invention are conventionally purchased raw materials and reagents.
[0042] N-Fluorenylmethoxycarbonyl-L-2-amino-5-phenylpentanoic acid was purchased from Aikon Yanxuan with CAS number 959578-11-1 and product number AK00H6I7.
[0043] SPF-grade high-fat and high-cholesterol feed was purchased from Guangdong Medical Experimental Animal Center, with the following ratio: 10% casein, 0.4% stone powder, 0.4% premix, 52.2% basic feed, 20% sucrose, 15% lard, 0.6% calcium hydrogen phosphate, 1.2% cholesterol, and 0.2% sodium cholate.
[0044] SPF level mouse feed, purchased from Guangdong Medical Experimental Animal Center, composed of raw materials such as corn, soybean meal, flour, wheat middlings, Peruvian fish meal, American chicken meal, calcium hydrogen phosphate, stone powder, sodium chloride, vegetable oil, vitamins, amino acids and minerals, etc.
[0045] Serum total cholesterol (TC) detection kit, triglyceride (TG) detection kit, high-density lipoprotein cholesterol (HDL-C) detection kit, low-density lipoprotein cholesterol (LDL-C) detection kit, and oxidized low-density lipoprotein (Ox-LDL) detection kit were purchased from Nanjing Jiancheng, with batch numbers 20240326, 20240326, 20241119, 20241118, and 20241019, respectively.
[0046] Example 1 1. Preparation of hyperlipidemia mouse model and grouping and administration Fifty healthy SPF male C57BL / 6 mice, weighing 18-22 g, were purchased from Guangdong Medical Experimental Animal Center and raised in the SPF animal laboratory of Guangdong Second Hospital of Traditional Chinese Medicine (Guangdong Institute of Traditional Chinese Medicine Engineering Technology), with the temperature always maintained at 20-25℃ and the relative humidity controlled at 50%-60%. After one week of adaptive feeding, ten mice were randomly selected as the normal group (Control) and given SPF level maintenance mouse feed, and the remaining 40 mice were given a high-fat high-cholesterol diet at a dose of 2 g·mouse -1 ·d -1 Modeling was performed for 4 consecutive weeks. At the end of the fourth week, blood was collected from the orbital venous plexus of the mice, and the serum was separated by centrifugation and used to determine the serum TC. The TC level of the mice in the modeling group was determined before grouping, and a significant difference compared with the TC level of the mice in the normal group indicated successful modeling. After successful modeling, the mice were randomly divided into a model group (Model), an atorvastatin group (AT, 2.6 mg·kg -1 ), an F2A5PP-H group (N-Fluorenylmethoxycarbonyl-L-2-amino-5-phenylvaleric acid F2A5PP, 52 mg·kg -1 ), and an F2A5PP-L group (N-Fluorenylmethoxycarbonyl-L-2-amino-5-phenylvaleric acid F2A5PP, 13 mg·kg -1 ), each containing 10 mice. Each administration group was given the corresponding drug by gavage at the dose every day, and the normal group and the model group were given the same volume of distilled water once a day for 4 consecutive weeks. During the administration period, the modeling method for the mice in each group was the same as described above.
[0047] 2. Detection of related blood indicators: 12 h before the last administration, the mice were fasted but not watered. 1 h after the last administration, the body weight of the mice was recorded, the mice were anesthetized, the eyeballs were removed, and blood was taken. The blood was centrifuged at 3000 rpm for 10 min, and the serum was taken. According to the kit instructions, the contents of serum total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and oxidized low-density lipoprotein (Ox-LDL) were detected.
[0048] 3. Statistical analysis The data were analyzed and statistically analyzed using SPSS 27.0 software. The normal measurement data were expressed as ± s , the mean values between multiple groups were compared using one-way ANOVA, and the mean values between groups were compared using SNK test. P <0.05 indicates that the difference between groups is significant. Statistical visualization column chart processing was completed using GraphPad Prism 10.
[0049] Example 2 N-Fluorenylmethoxycarbonyl-L-2-amino-5-phenylvaleric acid on the effect of blood lipid regulation in mice: The contents of total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and oxidized low-density lipoprotein (Ox-LDL) in the serum of mice in each group were as follows: ± s , n =10) are shown in Table 1 and Figures 1-5 , wherein, compared with the normal group (Control), *P<0.05, **P<0.01. Compared with the model group (Model), #P<0.05, ##P<0.01. Wherein, ns indicates no significant difference.
[0050] Table 1
[0051] Table 1 and Figures 1-5The results show that, compared with the normal group (Control) group, the total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C) and oxidized low density lipoprotein (Ox-LDL) levels in the serum of the model group (Model) mice are obviously increased (P<0.01), verifying the success of the high blood fat mouse modeling. Compared with the model group (Model) group, the total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C) and oxidized low density lipoprotein (Ox-LDL) levels in the serum of the F2A5PP-H group, the F2A5PP-L group and the positive drug atorvastatin group (AT) mice are obviously decreased (P<0.01 or P<0.05), and the high density lipoprotein cholesterol (HDL-C) level is obviously increased (P<0.05). The results suggest that N-Fluorenylmethoxycarbonyl-L-2-amino-5-phenylvaleric acid can improve the blood lipid level in the serum of the high blood fat mice induced by high-fat high-cholesterol diet.
[0052] It can be seen that N-Fluorenylmethoxycarbonyl-L-2-amino-5-phenylvaleric acid has the effects of reducing the total cholesterol, triglyceride and low density lipoprotein cholesterol in the serum and increasing the high density lipoprotein cholesterol in the serum, and based on this, N-Fluorenylmethoxycarbonyl-L-2-amino-5-phenylvaleric acid or a pharmaceutical composition thereof can be applied to prepare a medicine for reducing the total cholesterol in the serum, a medicine for reducing the triglyceride in the serum, a medicine for reducing the low density lipoprotein cholesterol in the serum or a medicine for increasing the high density lipoprotein cholesterol in the serum, and provide an effective new means and new way for preparing a medicine for preventing or treating hyperlipidemia.
[0053] Obviously, the above embodiments of the present application are only examples for clearly illustrating the present application, and are not intended to limit the embodiments of the present application. Based on the above description, other different forms of changes or variations can be made by those skilled in the art. Here, all the embodiments are not required to be exhausted. Any modification, equivalent replacement and improvement made within the spirit and principle of the present application should be included in the protection scope of the claims of the present application.
Claims
1. A pharmaceutical composition, characterized by, N-Fluorenylmethoxycarbonyl-L-2-amino-5-phenylpentanoic acid and pharmaceutically acceptable excipients, said N-Fluorenylmethoxycarbonyl-L-2-amino-5-phenylpentanoic acid having a structural formula as shown in formula (I): Formula (I).
2. The pharmaceutical composition according to claim 1, wherein The pharmaceutically acceptable excipients include pharmaceutically acceptable salts or esters.
3. The pharmaceutical composition according to claim 2, wherein The pharmaceutically acceptable salts are choline salt compounds.
4. The pharmaceutical composition according to claim 2, wherein The pharmaceutically acceptable esters are isopropyl ester compounds.
5. Use of N- fluorenylmethyloxycarbonyl-L-2-amino-5-phenylvaleric acid or a pharmaceutical composition as claimed in any one of claims 1 to 4 for the preparation of a medicament for lowering total cholesterol in serum, characterized in that, N-Fluorenylmethoxycarbonyl-L-2-amino-5-phenylpentanoic acid and pharmaceutically acceptable excipients, said N-Fluorenylmethoxycarbonyl-L-2-amino-5-phenylpentanoic acid having a structural formula as shown in formula (I): Formula (I).
6. Use of N- fluorenylmethyloxycarbonyl-L-2-amino-5-phenylpentanoic acid or a pharmaceutical composition as claimed in any one of claims 1 to 4 for the preparation of a medicament for lowering serum triglycerides, characterized in that, N-Fluorenylmethoxycarbonyl-L-2-amino-5-phenylpentanoic acid and pharmaceutically acceptable excipients, said N-Fluorenylmethoxycarbonyl-L-2-amino-5-phenylpentanoic acid having a structural formula as shown in formula (I): Formula (I).
7. Use of N- fluorenylmethyloxycarbonyl-L-2-amino-5-phenylpentanoic acid or a pharmaceutical composition as claimed in any one of claims 1 to 4 for the preparation of a medicament for lowering low density lipoprotein cholesterol in serum, characterized in that, N-Fluorenylmethoxycarbonyl-L-2-amino-5-phenylpentanoic acid and pharmaceutically acceptable excipients, said N-Fluorenylmethoxycarbonyl-L-2-amino-5-phenylpentanoic acid having a structural formula as shown in formula (I): Formula (I).
8. Use of N-9-fluorenylmethyloxycarbonyl-L-2-amino-5-phenylpentanoic acid or a pharmaceutical composition as claimed in any one of claims 1 to 4 for the preparation of a medicament for raising high density lipoprotein cholesterol in serum, characterized in that, N-Fluorenylmethoxycarbonyl-L-2-amino-5-phenylpentanoic acid and pharmaceutically acceptable excipients, said N-Fluorenylmethoxycarbonyl-L-2-amino-5-phenylpentanoic acid having a structural formula as shown in formula (I): Formula (I).
9. Use of N- fluorenylmethyloxycarbonyl-L-2-amino-5-phenylpentanoic acid or a pharmaceutical composition as claimed in any one of claims 1 to 4 for the manufacture of a medicament for the prophylaxis or treatment of hyperlipidemia, characterized in that, N-Fluorenylmethoxycarbonyl-L-2-amino-5-phenylpentanoic acid and pharmaceutically acceptable excipients, said N-Fluorenylmethoxycarbonyl-L-2-amino-5-phenylpentanoic acid having a structural formula as shown in formula (I): Formula (I).
10. Use according to any one of claims 5 to 9, characterized in that: The pharmaceutically acceptable excipients further include pharmaceutically acceptable carriers.
Citation Information
Cited By
Use of 5-phenylpentanoic acid for the preparation of a medicament
CN122537345A
